DE68910956D1 - Mit toxin modifizierter antikörper. - Google Patents

Mit toxin modifizierter antikörper.

Info

Publication number
DE68910956D1
DE68910956D1 DE89907264T DE68910956T DE68910956D1 DE 68910956 D1 DE68910956 D1 DE 68910956D1 DE 89907264 T DE89907264 T DE 89907264T DE 68910956 T DE68910956 T DE 68910956T DE 68910956 D1 DE68910956 D1 DE 68910956D1
Authority
DE
Germany
Prior art keywords
toxin
antibody modified
antibody
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89907264T
Other languages
English (en)
Other versions
DE68910956T2 (de
Inventor
Shuzo Matsushita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE68910956D1 publication Critical patent/DE68910956D1/de
Application granted granted Critical
Publication of DE68910956T2 publication Critical patent/DE68910956T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE68910956T 1988-06-10 1989-06-09 Mit toxin modifizierter antikörper. Expired - Fee Related DE68910956T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14294888 1988-06-10
PCT/JP1989/000586 WO1989011869A1 (en) 1988-06-10 1989-06-09 Antibody modified with toxin

Publications (2)

Publication Number Publication Date
DE68910956D1 true DE68910956D1 (de) 1994-01-05
DE68910956T2 DE68910956T2 (de) 1994-07-07

Family

ID=15327373

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68910956T Expired - Fee Related DE68910956T2 (de) 1988-06-10 1989-06-09 Mit toxin modifizierter antikörper.

Country Status (6)

Country Link
EP (1) EP0381763B1 (de)
JP (1) JP2867279B2 (de)
AU (1) AU627468B2 (de)
CA (1) CA1339775C (de)
DE (1) DE68910956T2 (de)
WO (1) WO1989011869A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
ATE249846T1 (de) * 1998-06-29 2003-10-15 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
ATE57187T1 (de) * 1983-03-30 1990-10-15 Lilly Industries Ltd Vincaleukoblastin-derivate.
JPS61233700A (ja) * 1984-12-24 1986-10-17 ジエネンテク，インコ−ポレイテツド 分子クロ−ンされたエイズ関連ポリペプチド
IE63109B1 (en) * 1986-06-23 1995-03-22 Genetic Systems Corp Human monoclonal antibody to lymphadenopathy-associated virus
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
DE3885355T2 (de) * 1987-05-29 1994-06-01 Shuzo Matsushita Monoklonale Antikörper.
AU626087B2 (en) * 1987-07-17 1992-07-23 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species

Also Published As

Publication number Publication date
EP0381763A4 (en) 1991-11-21
AU627468B2 (en) 1992-08-27
EP0381763A1 (de) 1990-08-16
CA1339775C (en) 1998-03-24
JP2867279B2 (ja) 1999-03-08
EP0381763B1 (de) 1993-11-24
DE68910956T2 (de) 1994-07-07
WO1989011869A1 (en) 1989-12-14
AU3779789A (en) 1990-01-05

Similar Documents

Publication Publication Date Title
DE68914244T2 (de) Monoklonaler Antikörper.
NO890115D0 (no) Antigen-antistoff-konjugat.
DE69018801T2 (de) Chimärischer anti-cae-antikörper.
DE3879452T2 (de) Chimaere antikoerper.
DE68908432D1 (de) Schwellwertimmunoassay.
DE68917768D1 (de) Einsteckbare Klammer mit innenliegendem Mechanismus.
DE68923629T2 (de) MIS Bauelement mit zusätzlichem Gate.
DE68907121D1 (de) Beschleunigungsaufnehmer.
DE68918231T2 (de) Aufnahmegerät mit mehreren Entwicklungseinheiten.
DE68924883T2 (de) Mikroprozessor mit Befehlspipeline.
DE68905644D1 (de) Antibiotische substanz mit antitumorwirkung.
FI895287A0 (fi) Monoklonal antikropp mot fukosylkeramid.
DE58901847D1 (de) Beschleunigungsaufnehmer.
DE68910956T2 (de) Mit toxin modifizierter antikörper.
DK474189D0 (da) Antistof
NO890116D0 (no) Monoklonale antistoffer.
FI893928A (fi) Monoklonala motkroppar.
DE68912772T2 (de) Monoklonaler antikörper gegen entero-viren.
IT8821702A0 (it) Nuovo anticorpo monoclonale.
DE69023717D1 (de) Monoklonaler Antikörper.
DE69100435D1 (de) Drehbetaetigung mit reibschluss.
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
DE69009508T2 (de) Gashebel mit zweifacher Sicherheitsstellung.
DE68902749T2 (de) Einfaedler mit nadelhaltender einkerbung.
ATE87031T1 (de) Chimaere antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee